ULTIMATE-SHF trial (UdenafiL Therapy to Improve symptoMAtology, exercise Tolerance and hEmodynamics in patients with chronic systolic heart failure): study protocol for a randomized, placebo-controlled, double-blind trial

BACKGROUND: Over the last few years, the use of phosphodiesterase type 5 (PDE5) inhibitors has been expanded to management of various cardiovascular disorders beyond pulmonary arterial hypertension. This study is designed to investigate the ability of udenafil, a newly developed long-acting PDE5 inh...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Kyung-Hee, Kim, Hyung-Kwan, Hwang, In-Chang, Lee, Seung-Pyo, Cho, Hyun-Jai, Kang, Hyun-Jae, Kim, Yong-Jin, Sohn, Dae-Won
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2013
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3694004/
https://www.ncbi.nlm.nih.gov/pubmed/23799908
http://dx.doi.org/10.1186/1745-6215-14-188

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3694004/
https://www.ncbi.nlm.nih.gov/pubmed/23799908
http://dx.doi.org/10.1186/1745-6215-14-188

Ejemplares similares